Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of Relugolix biological activity fentanyl and propofol or dexmedetomidine infusion. MS-275 clinical trials Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of fentanyl and propofol or dexmedetomidine infusion. Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.
Related Posts
Ethyl picolinate, 99%
Product Name : Ethyl picolinate, 99%Synonym: IUPAC Name : ethyl pyridine-2-carboxylateCAS NO.:2524-52-9Molecular Weight : Molecular formula: C8H9NO2Smiles: CCOC(=O)C1=CC=CC=N1Description: Ethyl picolinate is used in the preparation of 2-Aminodihydro[1,3]thiazines as BACE 2 inhibitors which is used in the treatment of diabetes.Raludotatug It is also used as pharmaceutical intermediate.Prucalopride PMID:25804060
Uted from wear-time was shorter. In contrast, we found no distinction in duration of activity
Uted from wear-time was shorter. In contrast, we found no distinction in duration of activity bouts, variety of activity bouts per day, or intensity of your activity bouts when non-wear time was computed utilizing either 20, 30 or 60 consecutive minutes of zero counts on the accelerometer (see Table two). This suggests study cohorts and […]
Et al., 2013). This suggests that mutation Cx46G143R induces an important raise in the HC
Et al., 2013). This suggests that mutation Cx46G143R induces an important raise in the HC activity, possibly by modifying the interaction in between the CT and IL, which is related with HC opening (Ren et al., 2013). A doable explanation for the pathological Sordarin Autophagy mechanism of leaky Cx46 HCs is the fact that the […]